구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | nivolumab (Opdivo, Gemcitabine+ nivolumab) Seoul National University Hospital·Recurrent or Metastatic Nasopharyn… 1 trials |
|---|---|
Overview Program | Gemcitabine+ nivolumab |
Overview Company | Seoul National University Hospital |
Overview Modality | ANTIBODY |
Overview Target | Recurrent or Metastatic Nasopharyngeal C |
Overview Indication | Recurrent or Metastatic Nasopharyngeal Carcinom |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer.. Acute kidney injury is a common complication of many medical procedures, including those used in cancer treatment. Both chemotherapy and immunotherapy may result in deterioration of kidney function, which may lead to an increase in mortality among pati… |
Clinical Safety signal | Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer.. Acute kidney injury is a common complication of many medical procedures, including those used in cancer treatment. Both chemotherapy and immunotherapy may result in deterioration of kidney function, which may lead to an increase in mortality among pati… |
Clinical Selected reported efficacy | ORR 69.6% |
Clinical Reported ORR | 69.6% |
Clinical Result source | ClinicalTrials.gov NCT03451331 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03451331 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | nivolumab (Opdivo, Gemcitabine+ nivolumab) Seoul National University Hospital·Recurrent or Metastatic Nasopharyn… 1 trials |
|---|---|
Overview Program | Gemcitabine+ nivolumab |
Overview Company | Seoul National University Hospital |
Overview Modality | ANTIBODY |
Overview Target | Recurrent or Metastatic Nasopharyngeal C |
Overview Indication | Recurrent or Metastatic Nasopharyngeal Carcinom |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer.. Acute kidney injury is a common complication of many medical procedures, including those used in cancer treatment. Both chemotherapy and immunotherapy may result in deterioration of kidney function, which may lead to an increase in mortality among pati… |
Clinical Safety signal | Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer.. Acute kidney injury is a common complication of many medical procedures, including those used in cancer treatment. Both chemotherapy and immunotherapy may result in deterioration of kidney function, which may lead to an increase in mortality among pati… |
Clinical Selected reported efficacy | ORR 69.6% |
Clinical Reported ORR | 69.6% |
Clinical Result source | ClinicalTrials.gov NCT03451331 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03451331 |
추천 비교
추천 비교